06/18/2025 | Press release | Distributed by Public on 06/17/2025 18:13
- To media representatives -
FRONTEO Inc.
Representative Board of Directors President Masahiro Morimoto
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)
FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; Representative Board of Director and President: Masahiro Morimoto; hereinafter FRONTEO) has developed a new technology using its in-house specialized AI "KIBIT" for FRONTEO's AI drug discovery support service "Drug Discovery AI Factory (hereinafter "DDAIF")" and obtained a patent in Japan. This technology contributes to solutions such as target discovery, biomarker discovery, and indication discovery in DDAIF. It enables cross-disease pathway analysis and analysis that captures disease stage changes, and is one of the core technologies of DDAIF that contributes to more advanced mechanism of action analysis and improved analysis efficiency. As a result, the number of patents related to DDAIF has increased to 12 in total, including 4 in Japan, 3 in Korea, 2 in the United States, and 21 in Europe.
[Patent outline]
Patent name: Pathway analysis device, pathway analysis method, and pathway analysis program■ About FRONTEO Co., Ltd. URL: https://www.fronteo.com/
FRONTEO supports the judgment of experts in various fields who face social issues day and night through the provision of its proprietary specialized AI "KIBIT," and creates the starting point for innovation. Unlike general-purpose AI, our proprietary natural language processing technology (patented in Japan, the United States, and Europe) enables high-speed and high-precision analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps (visualizes the structure) the analyzed information, "KIBIT" can directly influence the insights of experts, and in recent years, KIBIT's technology has also been used in hypothesis generation and target discovery in drug discovery.
Through KIBIT's unique technology and approach, we aim to realize our philosophy of "providing solutions that do not overlook risks and opportunities hidden in records, and realizing fairness in the information society."Life science AI, Risk Management (Compliance Support Area,economic security field,Legal Tech AI field), DX (Professional Support Areas) and promotes social implementation in each of our businesses.
Founded in August 2003, listed on the Tokyo Stock Exchange Mothers (now Tokyo Stock Exchange Growth) on June 8, 2007. Has operations in Japan, the United States, South Korea, and Taiwan. Obtained a Type 6 medical device manufacturing and sales license and filed a controlled medical device sales notification. Capital: 26 yen (as of March 899,176, 2025).
*FRONTEO, KIBIT, and Drug Discovery AI Factory are trademarks or registered trademarks of FRONTEO in Japan, Europe, the United States, and Korea.